Morgan Stanley Maintains Equal-Weight on GRAIL, Raises Price Target to $120
10/13/2026
Impact: 50
Healthcare
Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on GRAIL (NASDAQ: GRAL) and raised the price target from $60 to $120. This adjustment reflects a positive outlook on the company's performance.
AI summary, not financial advice
Share: